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doi:10.1016/j.jtcvs.2005.12.049he excitement and controversy surrounding the use of embryonic stem cells
were captured by 2 outstanding scholars who presented their arguments in a
brilliant debate, genially and thoughtfully moderated by Bob Guyton of
tlanta, Chief of Cardiothoracic Surgery at Emory University. Their arguments are
ummarized here using the words of the debaters as much as possible. Both have
eviewed and approved this condensed version.
Pro: Paul Berg, Cahill Professor of Cancer Research at Stanford, won the Nobel
rize in Chemistry in 1980 for developing methods that make it possible to analyze
he structure and function of DNA and its role in the development of genetic
ngineering. Professor Berg opened the debate by expressing his hope, as a patient
ho has survived a heart attack, that stem cells could one day be used to repair the
njured myocardium. He then described the origin and capabilities of stem cells.
here is 1 tissue-specific stem cell in every 25,000 bone marrow cells, and one of
hese stem cells can rescue a mouse after lethal marrow ablation. They cannot
ifferentiate into other somatic cells such as cardiac, neural, or pancreatic cells. In
ontrast, embryonic stem cells are derived from a blastocyst, a relatively undiffer-
ntiated structure of 100 to 150 cells that develops 4 to 6 days after fertilization of
n oocyte—an egg cell. About 30 cells, comprising the inner cell mass of the
lastocyst, are pluripotent embryonic stem (ES) cells; they give rise to all of the cell
ypes of the adult organism. ES cells can be propagated in tissue culture, and they
etain their pluripotentiality during long periods of frozen storage. These attributes
ave made them an attractive starting point for therapies aimed at tissue regenera-
ion. Furthermore, ES cells can be induced to differentiate by manipulation of the
edium into neurons that can be implanted into the brain to make functional
lectrical connections and produce dopamine, beta islet cells of the pancreas that
roduce insulin, and cardiomyocyte clusters that can beat in rhythm.
Human trials, done mostly in Europe, mostly without any controls, have explored
he effect of infusing or injecting bone marrow–derived stem cells into the myo-
ardium of a few hundred heart attack survivors with heart failure. There have been
laims of varying degrees of clinical improvement in cardiac function, but without
ontrols this conclusion is dubious. What little clinical improvement has been seen,
owever, could not be ascribed to engraftment of the injected cells. It is likely that
rowth factors present in the bone marrow suspension secreted by the injected cells
re what would account for any apparent repair.1
By contrast there is clear and convincing evidence that injection of bone
arrow– derived cells does not give rise to myocytes. After injection of genetically
agged, fluorescent hematopoietic stem cells into an infarcted site, the only fluores-
ent cells in the myocardium were those that had adopted the classic hematopoietic
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Lates, and not those of myocytes.2 Many such negative
xperiments support the view that hematopoietic stem cells
o not transdifferentiate into myocytes.
With respect to the potential of using ES cells to repair
amaged hearts, a recent minireview in Cell states: “Em-
ryonic stem cells possess the capacity to differentiate into
ardiac myocytes that resemble fetal or embryonic cardiac
yocytes. Such cardiac myocytes flux calcium, have spon-
aneous action potentials, spontaneously contract, and they
ill engraft and electrically and mechanically couple to host
ardiac myocytes when transplanted into the heart.”3 De-
pite such desirable properties, attempts to use ES cells
linically have been avoided because of the ethical storm
hat has been raised about the derivation of ES cells and the
ear that the injection of ES cells into the heart might
roduce teratomas and cardiac arrhythmias. Nevertheless, 1
uch attempt by Weissman and Robins at Stanford has
hown considerable promise. They injected allogeneic fluo-
escently labeled mouse ES cells into mice whose hearts’
eft anterior descending artery had been ligated. Examina-
ion of the infarcted site at varying periods revealed that
bout 50% of the infarcted area was populated by a dense
ollection of fluorescent cardiomyocytes expressing a char-
cteristic protein pattern. Coinjection of the ES cells with
rowth factors gave an enhanced effect, particularly in the
earts’ functional capacities.
By far the greatest impediment to the use of stem cells is
he histoincompatibility between the source of the cells and
he recipient. This is true for the use of adult-derived cells
rom an unmatched donor and cardiomyocytes derived from
S cells that can be obtained from the leftover embryos of
n vitro fertilization (IVF) clinics. It is for that reason that
e need to produce what Professor Berg refers to as
patient-specific” stem cells. The procedure for producing
uch patient-specific stem cells is still being worked out.
rogress along these lines has been slowed by ethical argu-
ents but more seriously is in danger of being made a
riminal offense. The derivation of patient-specific stem
ells is the process that has been erroneously referred to as
therapeutic cloning.” Professor Berg prefers to refer to it as
he “production of patient-specific stem cells” because that
s the intent. The process is quite straightforward and can be
ade quite efficient in production of specific stem cell lines
hat are matched to any 1 individual. The process involves
aking an unfertilized egg, harvested from a woman by
ormal procedures in an IVF clinic, and removing the
ucleus. The nucleus is replaced by another derived from
ny cell from the patient to be treated. With some fre-
uency, this reconstituted, nucleated egg undergoes cell
ivision, forms the blastocyst and produces a batch of ES
ells. Those ES cells have the same genetic makeup as the
ndividual who contributed the nucleus and it is these so-
alled patient-derived stem cells that we can foresee as b
38 The Journal of Thoracic and Cardiovascular Surgery ● Mayeing the root for therapies to avoid the histoincompatibility
roblem that would occur if one transferred cells that are
ow available in culture or from transfer of adult stem cells
nless those cells are derived from the patients themselves.
o far that seems unlikely.
Con: Eric Cohen is Director of the Biotechnology and
merican Democracy program at the Ethics and Public
olicy Center in Washington, DC, editor of The New
tlantis (a journal about the ethical, political, and social
mplications of technological advancement), and Consultant
o the President’s Council on Bioethics. Cohen framed the
uestion before us as whether this particular means of
dvancement, the creation and destruction of human em-
ryos, is an ethically responsible approach. The embryo
esearch debate has raised fundamental questions about the
spirations of medicine, the meaning of equality, the origin
f human life, and the spirit of human progress.
The embryo, the smallest human organism, sets before us
he biggest questions. Whether we should create and destroy
loned human embryos for research is a moral question that
cientists cannot answer with scientific principles. Citizens
ust answer, based on ethical principles and ethical reason-
ng. A responsible public debate requires 3 things: honest
cience, honest language, and careful ethical reasoning.
Honest science is unclouded by excesses of enthusiasm.
ype and hope ran ahead of reality in the gene therapy and
etal tissue debates and may be doing so in the embryonic
tem cell debate. The fairy tale that stem cells are the most
romising approach to curing Alzheimer’s disease has been
epeated over and over, most prominently in the recent
lection campaign in California.
Second, we need honest language. “Nuclear transfer to
roduce stem cells” is an accurate technical account, but it
isses the fundamental ethical question. To engage in nu-
lear transfer, you have to produce and destroy a cloned
uman embryo, and that is the heart of the public debate.
Third, we need careful ethical reasoning. It is ironic that
hose who see embryos as insignificant (no bigger than the
eriod at the end of this sentence when stem cells are
arvested) also desperately want them; it is not an ethical
rgument for why human embryos should be available for
ur use and destruction. Pursuit of a cure is an ethical goal
ut is not by itself a moral argument for why this particular
eans is ethically justified. The very powers of differenti-
tion that embryos possess when turned into embryonic
tem cells might be inseparable from the kind of beings that
hey are.
All of us hold dear the principle of human equality—that
ll human individuals, old and young, weak and strong,
ulnerable and healthy, possess a dignity that makes them
nviolable. This principle places a claim on us as members
f society that we should not discriminate against people
ased on certain missing attributes. If we trace back our own
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Levelopment from adulthood to infancy to the embryonic
tage, we have to ask ourselves “at what point did I come
nto existence?” After conception, there are significant
oments—when an embryo takes a discernable form, or
hen developing life can first begin to feel suffering. These
re not changes that mark the emergence of a new human
erson but the arrival of certain attributes in an existing
erson. To treat the weakest human beings as things avail-
ble for our use would violate the principle of human
quality upon which a decent democratic society rests.
Eric Cohen wondered whether it is good medicine to
dvise women to be a source of oocytes, engaging in a
rocedure that is not high risk but not without risks. What
ind of a society will we be if we create a huge market for
uman eggs, or base the advancement of medicine on their
vailability? Though we’ll try to set limits to prevent repro-
uctive cloning, as many nations already have, we have to
sk ourselves if it is wise to have the best scientists in the
orld publishing articles that make their technological
nowledge available to rogue scientists who will break
hatever policies we put in place.
Doctors have to be not only curers, but caregivers. This
equires an understanding of what it means to age, grow
rail, and get sick—to be aware of one’s own coming
ortality. These fundamental human sensibilities of a good
octor cannot be supplied by science. A physician’s under-
tanding of limits includes the idea that there are certain
hings a doctor cannot do, even if it would cure a patient.
e do not harvest organs recklessly; we do not have a
arket in organs, even though it would increase the supply.
reating a market for human embryos may change society.
e need to ask what kind of a society we would become if
e began using the seeds of the next generation as tools to
erve our own or if we laid the foundation of medical
rogress on the creation and destruction of cloned human
mbryos.
Rebuttals: Paul Berg described mutations that predis-
ose to early Alzheimer’s disease. Creating embryonic stem
ell lines with these mutations would allow mapping the
iochemical pathways and exploration of methods to treat
nd even prevent the disease. Although there is no evidence
hat stem cells have cured disease, there are proof of prin-
iple experiments in mice that they can be differentiated
nto dopamine-producing neurons and insulin-producing
eta cells and can help repair a damaged spinal cord. He
arned against proposed legislation to criminalize stem cell
esearch—threatening US citizens with $10,000,000 fines
nd 10 years in prison if they access patient-specific stem
ell therapy in countries like Britain that are developing this
echnology. Professor Berg cited prominent prolife advo-
ate Senator Warren Hatch, who makes a moral distinction
etween the blastocyst in the uterus and the blastocyst in a
etri dish. Hatch feels that using stem cells for therapies that r
The Journal of Thoracicay cure tens of thousands of people is more prolife than
pposing their use. Berg closed with an optimistic report
rom South Korea, where somatic cell nuclear transfer re-
earchers describe efficient propagation of stable long-term
tem cell lines from 1 in 3 to 4 eggs. (This report, subse-
uently shown to be fraudulent, has been retracted.)
Cohen granted that Alzheimer’s stem cell lines would
llow scientists to study the disease but then quoted the
estimony of a leading expert in Alzheimer research, Dennis
elcoe of Harvard Medical School. Selcoe told the Presi-
ent’s Council on Bioethics that stem cells are very far from
eing the most promising avenue for curing Alzheimer’s,
nd presenting it as being so is an irresponsible way to engage
n this public debate. Cohen emphasized that America does not
ave a ban on stem cell research; in fact it has the most
nregulated environment in this area, arguably, of any civ-
lized nation of the world. He clarified the prohibition
gainst using National Institutes of Health funds for embry-
nic stem cell research, emphasizing that the debate is about
hether citizens who believe that this research is wrong
hould be forced to pay for it through the public purse.
Audience discussion: Gus Mavroudis, from Chicago,
ited two US legal precedents related to abortion: (1) the
egal and moral standing of the fetus, and by inference that
f the blastocyst, ranks below that of the mother when
regnancy endangers her life; (2) survivability outside the
terus is an accepted legal threshold for personhood. Eric
ohen responded that in embryo research, there is no direct
onflict between the life of an ex vivo embryo and the life
f a mother. The researcher does not triage the life of this
mbryo versus the life of a particular patient. In contrast,
mbryo research involves a speculative project without gen-
ine evidence that it might cure hypothetical future patients.
iability is not the key issue, as even a young infant, once
orn, could not survive on its own if abandoned. The issue
s what do we owe to a living human organism, a life in
rocess, as those to whom its care has been entrusted. Paul
erg responded that many religions define personhood later
n gestation, and the Jewish religion makes curing the ail-
ents of living people a moral imperative. He indicated that
any countries, including Britain, Singapore, South Korea,
srael, and Australia, and many US states, have passed
egislation to enable embryonic stem cell research to go
orward.
Claudio Guareschi, from Greenville, SC, compared the
tatus of the neurologically undeveloped embryo as a tissue
onor to the brain-dead organ donor. Eric Cohen responded
ith a moral distinction between donors whose cognitive
unction has ceased forever and embryos that are develop-
ng toward full cognitive function. He closed by acknowl-
dging that our visceral reaction to the embryo in the petri
ish, which we can barely see, is different from our emotional
esponse to the sick person we know and love and desper-
and Cardiovascular Surgery ● Volume 131, Number 5 939
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Ltely want to save. Reminding us that an emotion is not a
oral argument, he recommended that we err on the side of
ife, and a basic commitment to human equality, by seeking
ther avenues to advance modern medicine.
Comment: President Tirone David and the AATS Coun-
il took a courageous step when they accepted the sugges-
ion from the Ethics Forum that this polarizing ethical issue
e debated at the 2005 Annual Meeting. An “issue” is an
mportant social question on which reasonable and fair-
inded people can disagree. Issues arise in professional
iscourse and clinical practice. These can generally be re-
olved by recourse to facts. In public policy, governance,
nd ethics, values have a more dominant role in settling
ssues. In the debate about using embryonic stem cells to
epair the injured heart, the facts set forth and logically
rgued by Professor Berg lead inexorably to the conclusion
hat embryonic stem cells will be able to repair the injured
yocardium. Eric Cohen’s value-based counterargument is
qually compelling, that killing a human embryo to harvest
tem cells will violate the most fundamental value of a just,
emocratic society and a caring profession—the preserva-
ion of even the most vulnerable of human lives. His posi-
ion was based entirely on classical democratic principles
ather than religious faith.
This is a classic ethical dilemma. Literally, a dilemma
omprises two “lemmas”—logical arguments based on
ound premises—that lead to contradictory conclusions. In
his debate the conclusions are contrary rather than contra-
ictory; they disagree but do not mutually exclude. If stem
ells could be harvested and propagated without terminating
he life of an embryo, resolution could be achieved, in the
ame way that we resolve the issue of harm to the donor for
he benefit of the recipient of an organ transplant. We
emove 1 kidney or 1 lobe of the lung or liver without
acrificing the life or long-term well-being of the donor. The
echnology is now well developed for removing a few
mbryonic cells at the 8- to 16-cell stage of development
fter in vitro fertilization for diagnosis of genetic disease and
election of healthy embryos. Implanting the embryo after this
n vitro intervention results in healthy babies.4 I share Professor
erg’s trust in scientific progress; I believe that harvest of stem
ells will become feasible without harm to the donor em-
ryo. This solution will not fully resolve the moral problem
f creating and destroying human lives, as described by Eric
ohen, unless the unharmed embryo is not destroyed.
The alternative of redefining the boundary of human life
y a socially constructed agreement (eg, 14 weeks’ gesta-
ion, etc) has been used very effectively for social purposes
t the other end of life—to harvest vital organs from those
onsidered to be brain dead. The moral reasoning elaborated
y Eric Cohen would allow that boundary at the end of life
o be advanced because there is no prospect of recovery, but
onsensus on brain death is incomplete. Not all jurisdic- 5
40 The Journal of Thoracic and Cardiovascular Surgery ● Mayions, religions, and cultures accept brain death. Pioneering
ardiac surgeon Juro Wada was charged with murder in
apan for harvesting the heart of a donor who was “dead”
nly by Western neurological criteria. The useful social
onstruction of a redefinition of death as brain death has
llowed us to harvest vital organs from patients whose heart
s beating, assuring their corporeal death. This has brought
he gift of life to recipients, but those who harvest know that
n uneasy, almost complicit silence usually falls over the
oom after removal of the heart and lungs. That silence is a
equiem, rooted in a deeply ingrained cultural reverence for
ife, what Leon Kass, the Chairman of President George W.
ush’s Council on Bioethics, has called the “life principle.”
will close with his recent comments about the Council’s
eport: “Important though it is, the ‘life principle’ cannot
ontinue to be the sole consideration in public bioethical
iscourse. Some efforts to prolong life may come at the
rice of its degradation, the unintended consequences of
uccess at life-saving interventions. Other efforts to save
ives might call for dubious or immoral means, while the
attle against death itself—as if it were just one more
isease—could undermine the belief that it matters less how
ong one lives than how well. At the beginning of life,
ertain modes of conceiving children—for example, by
loning—threaten human dignity, even if no embryonic
ives should be lost in the process. And, in extreme circum-
tances, perhaps, lives may even need to be risked or even
acrificed so that the community might survive and flourish.
uch questions of the good life—of humanization and de-
umanization—are of paramount importance to the field of
ioethics and to the future of our nation and the human
ace.”5
I’m convinced that good faith efforts, respectful of op-
osing values and beliefs, will lead us to an acceptable
esolution. In the interim, this outstanding debate is avail-
ble to be viewed in more detail at www.aats.org/2005we-
cast/wednesday.html. The Webcast will help you think
bout this important issue using clearly articulated scientific
nd value-based conceptual frameworks. You will be in-
pired by the speakers and proud of the profession.
I am grateful to Deborah McKneally for helpful suggestions
hat improved earlier versions of this manuscript.
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